154P Investigation of PD-L1 expression and tislelizumab efficacy in gastroesophageal adenocarcinoma using a novel tumor and immune cell score with VENTANA PD-L1 (SP263) assay and Combined Positive Score (CPS)

Y Chao,S Yang,Y Zhang,Z Shen,X Wu,J Wang,M Quiroz,A Nielsen,C Liu,J Desai

doi:10.1016/j.annonc.2020.08.275

154P Investigation of PD-L1 expression and tislelizumab efficacy in gastroesophageal adenocarcinoma using a novel tumor and immune cell score with VENTANA PD-L1 (SP263) assay and Combined Positive Score (CPS)

Y Chao, S Yang + Show 8 more

Open Access

https://doi.org/10.1016/j.annonc.2020.08.275

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2020
Citations: 5	License type: elsevier-specific: oa user license

Affiliation: Taipei Veterans General Hospital, BeiGene (China), Ventana Research Corporation (United States), Roche (United States), Peter MacCallum Cancer Centre

#Immune Cell Score #Combined Positive Score + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

154P Investigation of PD-L1 expression and tislelizumab efficacy in gastroesophageal adenocarcinoma using a novel tumor and immune cell score with VENTANA PD-L1 (SP263) assay and Combined Positive Score (CPS)

Full Text